Amazon, Axon Enterprise, Google, Meta and Oracle backed expanding electronic prior authorization to self-funded employer health plans. The post Amazon, Google and Other Major Employers Back CMS Prior Auth Effort appeared first on MedCity News.

Alcon’s Neurotech Pharmaceuticals acquisition brings the rare vision disorder cell therapy Encelto as well as the platform technology that developed it. Last year, Alcon acquired a majority stake in Aurion Biotech, a startup developing a corneal cell therapy. The post Alcon Expands Its Cell Therapy Ambitions With $550M Neurotech Pharma Acquisition appeared first on MedCity News.

Throwing more money at SDoH programs isn’t going to magically fix them. Instead, plans should be focusing on building out these three specific capabilities that, together, can noticeably alter the playing field. The post Why SDoH Programs Fall Short — and What It Takes to Make Them Work appeared first on MedCity News.

In addition to a packed conference agenda and tours of the Pegasus Park healthcare and life science innovation hub in Dallas, INVEST Digital Health also includes an innovation showcase with novel health tech and medtech offerings as well as networking opportunities. The post INVEST Digital Health Celebrates Healthcare Innovation in Texas appeared first on MedCity News.

Judi Health launched Judi Rx Retire, an employer-sponsored Medicare Part D plan designed to improve pricing transparency and streamline benefits administration. The post Judi Health Launches Medicare Part D Plan for Employers appeared first on MedCity News.

GSK’s Hibsago brings a new mechanism of action to chronic hepatitis B, targeting the genetic instructions the virus uses to make copies of itself and viral proteins. This drug was licensed from antisense oligonucleotide specialist Ionis Pharmaceuticals. The post GSK Wins FDA Nod for Novel Hepatitis B Drug Offering a Potential Functional Cure appeared first on MedCity News.

As generative AI moves toward performing increasingly consequential clinical functions, the American Medical Association (AMA) is urging the U.S. Food and Drug Administration to address a foundational question: Who is responsible for ensuring that these tools remain safe once they enter clinical practice? The post AMA Calls for Risk-Based GenAI Oversight to Protect Patients and Support Responsible Innovation appeared first on MedCity News.

A patient’s automated risk score was reassuringly green. Pulling from a sparse medical record and infrequent acute visits, the model flagged him as low risk and routed him to the default, low-touch outpatient pathway — so why was the patient actively deteriorating? The post Your Product Works — So Why Does It Still Fail in the Real World? appeared first on MedCity News.

Rick Abramson, a radiologist by training and the director of FDA’s Digital Health Center of Excellence said, “We ended up putting out this idea that maybe these devices are starting to behave a little bit more like me as a physician than a heart valve or a defibrillator.” The post FDA Official Believes GenAI-enabled Tools Will Need to Be Assessed Like a Physician appeared first on MedCity News.

The Series A round was led by Define Ventures, with participation from Y Combinator and the California Health Care Foundation Innovation Fund. The post Readily Secures $11M for Compliance Intelligence Platform appeared first on MedCity News.

The GSK cancer immunotherapy Jemperli is now approved for treating advanced cases of rectal cancer harboring a particular genetic signature. It’s a label expansion for Jemperli, which was initially approved as a treatment for endometrial cancer. The post GSK Immunotherapy Gets Accelerated FDA Approval for Treating Rectal Cancer appeared first on MedCity News.

Cell and gene therapies are amazing medical breakthroughs but if we don’t find ways to pay for them, the development pipeline will fail. The post A Radical Proposal to Preserve Cell and Gene Therapy Innovation appeared first on MedCity News.

A new report on third quarter M&A activity in the healthcare sector found that this quarter’s hospital and health system transactions remained steady, with 2026 potentially set to be a top year for total annual transactions since pre-pandemic times. The post Report: Health System M&A Activity Remains Steady in Third Quarter appeared first on MedCity News.

AdvaMed CEO Scott Whitaker outlined four policy priorities at the MedTech Conference: tariffs, FDA user fees, payment and coverage, and cybersecurity. The post AdvaMed’s 4 Policy Priorities, According to Its CEO appeared first on MedCity News.

The Silence Therapeutics acquisition gives Merck KGaA a drug ready for a pivotal test in the blood disorder polycythemia vera. Silence’s RNA therapy offers a different approach and a potential dosing advantage over a Takeda Pharmaceutical product recently approved in this indication. The post Merck KGaA’s $1.1B Silence Therapeutics Buyout Brings RNA Drug for Rare Blood Cancer appeared first on MedCity News.